Browse Category

ASX:CSL.AX 7 January 2026 - 26 February 2026

CSL share price edges up as buyback keeps ASX heavyweight in play

CSL share price edges up as buyback keeps ASX heavyweight in play

CSL Ltd shares closed up 0.6% at A$146.02 Thursday, near the bottom of their 52-week range. The company disclosed it bought back 79,031 shares Wednesday for about A$11.5 million, bringing total repurchases since September to 3.70 million shares. CSL’s half-year report earlier this month showed a 7% drop in underlying NPATA and US$1.1 billion in after-tax impairments. The stock trades ex-dividend March 10.
Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

CSL shares closed up 0.95% at A$154.19 in Sydney, marking a second consecutive gain after announcing a US$100 million licensing deal with Eli Lilly for clazakizumab. ASX filings showed CSL continued its share buyback and a director increased holdings. The stock remains about 15% below early-February levels. CEO Paul McKenzie is set to retire, with Gordon Naylor named interim chief.
CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL said CEO Paul McKenzie will retire, appointing Gordon Naylor as interim chief from Feb. 11. Shares closed down 4.98% after the announcement, which came after market close. Naylor, a former Seqirus and finance head, will lead Wednesday’s half-year results briefing. The leadership change follows weak U.S. flu vaccine demand and delayed plans to spin off Seqirus.
CSL share price ends higher after Vanguard lifts stake — here’s what to watch next

CSL share price ends higher after Vanguard lifts stake — here’s what to watch next

CSL Limited closed up 1.13% at A$181.42 in Sydney, with shares moving on sector momentum and increased institutional ownership after Vanguard disclosed a 6% stake. No new trading update was issued. Investors await CSL’s half-year results and interim dividend announcement on Feb. 11. The stock remains volatile after an October profit downgrade and vaccine unit spin-off delay.
31 January 2026
CSL share price ticks higher — but the real test is Feb 11

CSL share price ticks higher — but the real test is Feb 11

CSL Ltd shares closed up 0.46% at A$175.10 on Monday, with about 376,000 shares traded. The move comes ahead of CSL’s half-year results and interim dividend announcement set for Feb. 11. The S&P/ASX 200 finished 0.48% higher, led by gold and consumer stocks, as spot gold hit a 2026 record. CSL’s outlook remains cautious after last year’s guidance cut and delayed Seqirus spin-off.
12 January 2026
Go toTop